NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,823.14 mln
Float31.26 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
53.60
Exceptional upside
Relative Strength
74
/ 100
Outperforming
Debt / Equity
0.02
Debt-free
ROE
-30.11
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Rapport Therapeutics is a Boston-based clinical-stage company working to develop new treatments for disorders of the brain and nervous system. Its lead drug candidate, RAP-219, targets specific receptors in the brain and is being studied as a potential therapy for focal epilepsy, neuropathic pain, and bipolar disorder. The company is also advancing separate research programs aimed at addressing chronic pain, migraines, and hearing and balance disorders.
